Hori T, Abe S, Baba A, Suzuki T, Shiraishi H
Department of Psychiatry, Institute of Clinical Medicine, The University of Tsukuba, Tsukuba City, Ibaraki, Japan.
Neurosci Lett. 2000 Feb 11;280(1):53-6. doi: 10.1016/s0304-3940(99)00991-x.
Phencyclidine (PCP) is known to be an inhibitor of serotonin (5-HT) uptake and to increase serotonergic activity. The development of tolerance to serotonergic stereotyped behaviors induced by repeated PCP treatment and changes of 5-HT transporters were examined. Backpedalling was significantly reduced in frequency following 14 days PCP treatment (7.5 mg/kg per day). Furthermore, repeated PCP treatment decreased the equilibrium dissociation constant (Kd) of [3H]paroxetine binding to 5-HT transporters in whole brain excluding the cerebellum without any change of maximum number of binding sites (Bmax). Single treatment with PCP failed to change binding parameters. These results indicate that repeated PCP treatment causes tolerance in serotonergic stereotyped behavior and increases affinity of 5-HT transporters for [3H]paroxetine binding. The increased affinity of 5-HT transporters could represent compensatory responses to chronic inhibition of 5-HT uptake by PCP.
苯环利定(PCP)已知是一种血清素(5-羟色胺,5-HT)摄取抑制剂,并能增强血清素能活性。研究了重复给予PCP治疗后对血清素能刻板行为的耐受性发展以及5-HT转运体的变化。在接受14天PCP治疗(每天7.5毫克/千克)后,倒退行为的频率显著降低。此外,重复给予PCP治疗可降低[3H]帕罗西汀与除小脑外的全脑5-HT转运体结合的平衡解离常数(Kd),而最大结合位点数(Bmax)无任何变化。单次给予PCP未能改变结合参数。这些结果表明,重复给予PCP治疗会导致血清素能刻板行为产生耐受性,并增加5-HT转运体对[3H]帕罗西汀结合的亲和力。5-HT转运体亲和力的增加可能代表了对PCP长期抑制5-HT摄取的代偿反应。